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ABSTRACT 
Interrogation of hematopoietic tissue at the clonal level has a rich history spanning over 50 years, and has 
provided critical insights into both normal and malignant hematopoiesis. Characterization of chromosomes 
identified some of the first genetic links to cancer with the discovery of chromosomal translocations in 
association with many hematological neoplasms. The unique accessibility of hematopoietic tissue and the 
ability to clonally expand hematopoietic progenitors in vitro has provided fundamental insights into the 
cellular hierarchy of normal hematopoiesis, as well as the functional impact of driver mutations in disease. 
Transplantation assays in murine models have enabled cellular assessment of the functional consequences 
of somatic mutations in vivo. Most recently, next-generation sequencing based assays have shown great 
promise in allowing multi ‘omic’ characterisation of single cells. Here we review how clonal approaches have 
advanced our understanding of disease development, focussing on the acquisition of somatic mutations, 
clonal selection, driver mutation cooperation and tumor evolution.  
 
INTRODUCTION 
Every cell division throughout life, starting from the first division of the fertilised egg, requires the accurate 
replication of the entire genome, which in humans comprises 3 billion nucleotide base pairs. Mammalian 
DNA replication and repair systems, whilst highly complex and precise, are not infallible. Ongoing exposure 
to endogenous and extrinsic DNA damaging insults inevitably results in the acquisition of somatic mutations 
in individual cells1. Thus, the DNA composition of cells within a tissue can be compared to a fine mosaic, 
each distinct tile of which is akin to an individual cell that differs from its neighbour by virtue of its unique 
catalogue of somatic mutations.  The vast majority of such mutations occur in non-coding regions of the 
DNA and are believed to have a neutral effect on cellular fitness2. However, mutations can lead to positive 
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selection and clonal expansion if they land in genomic regions, for example those with oncogenic potential, 
that result in cellular phenotypes which enhance fitness with respect to competing normal cells (termed 
‘driver’ mutations). Clonal expansion provides a reservoir for the acquisition of further driver mutations, and 
ultimately carcinogenesis. Thus, increasing somatic mutation poses a real threat to the organism, particularly 
when it concerns highly replicative tissues and long-lived species. 
  
Complex adaptive systems have evolved to reduce the burden of somatic mutation. Within the 
hematopoietic system, that produces billions of cells each day, long term self-renewal capacity is imparted 
only to hematopoietic stem cells (HSCs).  The necessary exponential burst of proliferative capacity required 
to maintain tissue output, is restricted to progenitor cells that are short lived. However, despite protective 
DNA repair mechanisms and a reduced replicative burden HSCs also accumulate mutations over their longer 
lifespan, which get immortalised in subsequent generations of daughter HSCs. The impact of such mutations 
within the HSC pool is challenging to characterise due to the rarity of the population, and the requirement 
for single-cell resolution. Indeed, much of our understanding of the consequences of somatic mutations on 
hematological disease development comes from studying hematopoietic cancers, where mutations in the 
tumor cell-of-origin are captured by virtue of the clonal expansion that subsequently occurs.  
  
Recent decades have witnessed genetic characterisation of tumors at unprecedented scale, resulting in an 
almost complete compendium of somatic mutations that drive human cancers3. However, two major 
challenges have become evident. First, cancer drivers are increasingly being identified in normal tissues, 
both solid organs4,5 and blood, from healthy individuals6–9.  This finding substantially blurs the distinction 
between normal physiology and the diseased state, and raises the possibility that mutation acquisition per 
se may not be the rate-limiting step for disease development.  Secondly, intra-tumor heterogeneity and 
subclonal evolution within tumors provides a major route to therapeutic resistance10. Genomic approaches 
applied to bulk tumor samples can estimate diversity within a tumor and, in some cases, the timing of genetic 
events11. However, a detailed understanding of the factors driving mutation acquisition, clonal selection and 
tumor evolution requires assessment of both normal, premalignant and malignant hematopoietic cell 
populations at the level of individual cells.  
 
In this review, we discuss a selection of clonal approaches and how they have provided valuable insights into 
both normal hematopoiesis and the development of hematological disorders.  The review is biased towards 
the myeloid malignancies, to which clonal approaches have predominantly been applied to date.  To avoid 
semantic confusion, we refer to a clone as comprising cells that descend from a common ancestor and share 
heritable genetic features. We use ‘lineage’ to refer to a cell’s ancestral line, as opposed to the various 
differentiated hematopoietic cell types.  ‘Mutation’ is used in its broadest sense, and includes somatically 
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acquired DNA single base-pair substitutions, insertions and deletions, copy-number changes and other 
chromosomal rearrangements.    
 
CLONAL APPROACHES 
Interrogation of tumors at the clonal level was pioneered in blood and has a rich history spanning over 50 
years (Figure 1).  The identification of the Philadelphia chromosome as a clonal abnormality in cells from 
patients with chronic myeloid leukemia, was seminal in implicating the first specific genetic mutation as a 
cause of cancer12. Subsequent cytogenetic techniques, such as Giemsa-banding of metaphase chromosomes 
and fluorescence in-situ hybridisation, identified a range of chromosomal lesions present in  many leukemias 
and lymphomas13.   
 
Studies of X-chromosome inactivation patterns have been another cornerstone of our understanding of the 
clonal origin of hematopoietic neoplasms. Expression studies of X-linked glucose-6-phosphate 
dehydrogenase (G6PD) in females genetically heterozygous for the G6PD locus were first used to study 
cancer in patients with leiomyomas. This work identified that tumor cells expressed only one G6PD allele, 
suggesting their unicellular, or clonal, origin14.  Similar findings were made in females with lymphoma15 and 
chronic myeloid leukemia16, and in the latter, the presence of monoallelic expression of G6PD across the 
different differentiated hematopoietic cell types further suggested that the tumor arose from a multi-potent 
stem cell16.  Such studies in polycythemia vera, a disease not previously recognised as being neoplastic, also 
established it as a clonal disorder arising in a multipotent progenitor or stem cell17.  Indeed, the recognised 
skewing of X-activation patterns often found in blood from elderly females paved the way for the subsequent 
discovery of age related clonal hematopoiesis6.  
 
Clonogenic assays involving the in vitro expansion of single myeloid progenitors were developed around the 
same time18, and helped define the hematopoietic cellular hierarchy we are familiar with today. Diluted 
bone marrow or peripheral blood derived mononuclear cells plated in semi-solid media and cultured in the 
presence of colony stimulating growth factors, result in the growth of distinct individual ‘colonies’. Each 
colony comprises a cluster of differentiated cells derived from a single progenitor cell. Using this approach, 
many myeloid diseases were dissected at the colony level in the 1970s. More recently, colonies of cells can 
also be grown in liquid culture within individual wells seeded with single cells of interest. The ability to isolate 
specific hematopoietic cell populations using flow cytometry, and the availability of an array of in vitro 
culture conditions, has since allowed the growth of colonies from specific starting hematopoietic 
populations and finer resolution of genotype-phenotype relationships.  These colony-based approaches 
overcome many of the challenges of single-cell experiments by generating a larger amount of clonal material. 
However, they do restrict assessment to those diseases in which the abnormal cells are able to grow in-vitro. 
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For example, acute leukemia blasts have been much more challenging to expand in such conditions than 
progenitors from the myeloproliferative neoplasms. 
 
The growth of clones in vivo rather than in vitro, using transplantation approaches in mice, offers the 
potential to assess the cellular consequences of mutations on disease development.  Growth of splenocyte 
colonies in the 1960s using donor cells traceable in recipient mice identified for the first time that different 
myeloid cell types are derived from a common multipotent hematopoietic progenitor cell19. Technical 
advances enabling single-cell transplantation assays are able to assess stem cell fitness and engraftment 
potential of individual cells harbouring specific mutations, albeit in the environmental context of an 
irradiated recipient20. Clones derived from human HSCs can also be characterised following 
xenotransplantation into mice21 using endogenous markers (eg specific genetic mutations or 
rearrangements), or by introducing markers22 (eg  lentiviral vectors23, genetic barcodes24). More recently, 
CRISPR scratchpads have been used for single-cell clonal tracing in zebrafish to dissect the embryonic 
relationships between adult cell types25. 
 
Single-nucleotide polymorphism arrays, and subsequently, next-generation sequencing techniques have 
revolutionised our ability to interrogate and characterise the genomes of tumors. Sequencing can cover the 
whole exome, whole genome, target specific genetic regions of interest, and characterise chromosomal 
copy-number changes within blood samples. Such sequencing approaches have identified sub-clonal copy-
number alterations26–28 and somatic mutations7,8,29,30 at increasing frequency with age in the blood of 
healthy individuals. Initially termed clonal mosaicism26,27,31, this is now recognised as the presence of age-
related clonal hematopoiesis that is distinct from clinically apparent hematological neoplasms32. Whilst 
studies employing increasing sensitivity and error-corrected sequencing have identified much higher rates 
of clonal hematopoiesis33,34, the true incidence of mutant HSCs within the marrow and how this is influenced 
by age currently remain unknown. 
  
Over the past few years molecular characterization of single cells has provided a powerful approach to 
assessing clonal evolution and clonal diversity across a range of hematological disorders35–37.  Single-cell 
whole-exome sequencing can be performed but suffers from both false-negative and false-positive 
mutations due to the paucity of genomic material and requirement for DNA amplification38,39. Given the 
recognition of molecular and cellular heterogeneity in tissues, combining information from both the genome 
and epigenome within the same cell is an area of intense technical development. Genomic and 
transcriptomic information can now be assessed in single cells (G&T-seq)40, and simultaneous measurement 
of genomic copy-number, DNA methylation and RNA content in single cells (scTrio-seq) is also 
feasible41.  Due to technical limitations these methods are yet to be applied widely. However, such 
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endeavours hold significant promise as it seems likely they will ultimately allow us to understand the 
functional consequences of mutations in the context of epigenetic and cellular heterogeneity.  
 
These clonal approaches have provided critical insights into both normal and malignant hematopoiesis. Here 
we review how they have contributed to our understanding of driver mutation acquisition, clonal expansion, 
the role of cooperating mutations, and the dynamics of tumor evolution.  
 
SOMATIC MUTATIONS IN HEMATOPOIETIC STEM CELLS 
Somatic mutations in cells are acquired in several ways. Cell-extrinsic mutagens include chemicals (such as 
tobacco, aflatoxin etc), ionizing radiation and ultra-violet light. Additionally, DNA is damaged via cell-
endogenous exposures to reactive oxygen species, inadequate function of DNA repair enzymes, abnormal 
activity of DNA-editing enzymes, and activity of viruses and retrotransposons1. Interestingly, hematopoietic 
tumors and some paediatric brain tumors carry the smallest number of somatic mutations across all human 
cancers42, suggesting that, compared to many other tissues,  HSCs are relatively well protected from this 
mutagenic onslaught. One key study performed whole-exome sequencing on hematopoietic colonies grown 
from cord blood or from individuals of varying ages, and identified a linear increase in mutation burden with 
age43. The number of somatic mutations found in acute myeloid leukemia (AML) in their study was close to 
that expected in a normal individual of the same age. These data provided two important insights: first, that 
most mutations detected in bulk AML samples represent those that have accumulated with age and were 
present prior to malignant transformation; and secondly, that background somatic mutation acquisition in 
HSCs can be viewed as a molecular clock, with the total number of mutations present reflecting the age of 
the individual. Whole-genome sequencing of colonies from normal bone marrow has identified that a large 
component of these background mutations involve C>T transitions in a CpG context which are the result of 
the time-dependent tendency towards spontaneous deamination of 5-methylcytosines over life44.  In 
addition, there is an excess of nucleotide transitions over transversions, typical of polymerase errors during 
DNA replication.  Some myeloid tumors show evidence of additional mutational processes, for example, 
mutations driven by chemotherapeutic agents10.  Such DNA damaging processes have been found to leave 
distinct ‘mutational signatures’ in the DNA1,45, and the mechanisms of DNA damage for some mutational 
processes have been further clarified using mutagenesis assays in cell lines and model organisms46–48. Future 
studies of these signatures at a clonal level are likely to identify intrinsic and extrinsic mechanisms that 
contribute to mutation acquisition  and reveal how they vary during development, with ageing, by 
microenvironmental context, and across different hematopoietic cell types.  
 
DRIVER MUTATION ACQUISITION 
Driver mutations are a tiny subset of somatic mutations that are found recurrently in tumors at specific 
genomic loci at a much higher frequency than would be expected by chance. In recent years, sequencing 
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studies of tissues have also identified the presence of driver mutations in healthy skin, oesophagus, colon, 
endometrium and blood4,5,7,8,29,39,49,50. The overwhelming majority of driver mutations identified to date 
affect protein-coding regions of the genome, with just a few reported in non-coding regions. However, most 
sequencing studies of cancers have focussed on tumor exomes, thus, leading to a discovery bias. From a 
smaller number of whole-genome studies, non-coding driver mutations have been discovered in cancers 
including hematological neoplasms. For example, mutations in regulatory regions affecting the expression 
of NOTCH1 and PAX5 in CLL51 and LMO2 in T-ALL52. Driver mutations perturb several molecular and cellular 
pathways53 and their identification has improved classification of hematological disease54,55. However, little 
is known about when driver mutations actually occur over the lifetime of an individual. Do driver mutations 
occur early in life but confer no clonal advantage until other cell-intrinsic or environmental changes result 
in realisation of their oncogenic potential or an enhanced cellular fitness compared to the normal stem cell 
pool? Alternatively, is chance acquisition of the first driver mutation the rate-limiting step in driving the 
development of clonal expansions and subsequent malignancy?  
 
The size of the cell population that is the target for acquisition of driver mutations, as well as the mutation 
rate in this pool of cells, are both central to estimating the rate at which driver mutations may be acquired. 
Lee-Six et al provide us with some estimates relating to HSC dynamics in steady-state human 
hematopoiesis44.  In this study, individual bone marrow derived colonies from a healthy 59 year old male 
underwent whole-genome sequencing, and the pattern of shared and unique somatic mutations in 
individual colonies was then used to derive a phylogenetic tree depicting the ancestral relationship between 
all the individual colonies.  Using methods adopted from population genetics, the size of the HSC pool was 
shown to expand during childhood and adolescence and then remain fairly stable over subsequent adult life. 
The total number of adult HSCs was estimated to be much larger than previously thought (between 44,000 
and 215,000), with each HSC dividing every 2-20 months and acquiring 1-2 somatic mutations per cell 
division44.  
 
Using these figures, one can begin to make rough estimates of the chance of randomly acquiring a driver 
mutation by 60 years of age. As shown in Figure 2, we estimate that there is a 0.5% to 2.4% chance of 
acquiring one driver mutation (single-nucleotide substitution) within the entire HSC pool by 60 years of age. 
This is of course over-simplified since it restricts the tumor cell-of-origin to only the HSC pool, and it accounts 
for neither variability in mutation rates across different genomic regions, nor tissue-specific mutational 
processes which have been demonstrated to play a role in acquiring driver mutations56. Nevertheless, this 
rough estimate of HSC driver mutation acquisition can be compared to the reported prevalence of driver 
mutations in blood from healthy individuals. For example, there may be some driver mutations that confer 
a strong enough selective advantage that their reported frequency in the general population might largely 
reflect their rate of acquisition in HSCs. Such drivers might include JAK2V617F or DNMT3AR882H, the frequency 
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of which appears to increase linearly with age, both reaching an incidence of 2-3% in 80-89 year olds29. In 
another study of ~50000 normal adults (median age 56), the frequency of JAK2V617F was 0.1% with the 
majority of patients subsequently developing evidence of a myeloproliferative neoplasm (MPN)57. These 
figures are consistent with estimates of the number and mutation rate of human HSCs (Figure 2). However, 
age-related clonal hematopoiesis can result from several other driver mutations, including loss-of-function 
mutations occurring across the entire length of the genes such as TET2, ASXL1 and DNMT3A7–9,29. 
Considering this, the reported prevalence of only ~5% for age-related clonal hematopoiesis (defined by a 
variant allele fraction >2% in blood) by 60 years of age across these studies appears somewhat lower than 
expected. Notwithstanding the observation that studies utilizing greater depth or error correction of 
sequencing reveal higher rates of clonal hematopoiesis, additional factors may also influence clonal 
expansion. 
 
CLONAL SELECTION AND EXPANSION 
Assuming a single somatic driver mutation has been acquired, it then becomes important to understand  
whether it is sufficient to result in clonal expansion and overt hematological disease and, if not, what 
additional permissive factors may be required.  
 
Whole-exome and targeted sequencing studies show that a significant proportion of patients with 
hematological neoplasms harbour only a single driver mutation. For example, MPNs are often found only to 
harbor mutated JAK2, CALR or MPL58. Similarly, the BCR-ABL translocation and the MLL rearrangement are 
commonly found as isolated genetic lesions in patients with chronic myeloid leukemia59,60 and infant acute 
lymphoblastic leukemia61,62 respectively.  This suggests that single mutations can drive disease phenotype 
in some hematological neoplasms, thus providing a window into the earliest stages of tumorigenesis. 
 
The MPNs in particular provide a powerful model for understanding how a single mutation results in a clinical 
phenotype due to their disease chronicity and the ready growth of hematopoietic colonies which allow intra-
patient comparisons with unmutated control colonies. Such approaches in MPNs have shown, inter alia,  
that: (i) JAK2V617F drives erythropoietin-independent BFU-e growth of cells from MPN patients63,64; (ii) 
JAK2V617F has distinct signalling and transcriptional consequences in patients with essential 
thrombocythemia compared to those with polycythemia vera65; (iii) clones harbouring homozygosity for 
JAK2V617F are a pathognomic feature of polycythemia vera highlighting the importance of gene dosage in 
determining phenotype66,67, and (iv) the order of acquisition of driver mutations also impacts their functional 
consequences as discussed later. 
 
In vivo murine transplantation assays have been used to address whether JAK2V617F is sufficient to drive 
clonal outgrowth. Using limiting-dilution transplants of JAK2V617F- positive murine cells, Lundberg et al64 have 
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shown that an MPN phenotype (either erythrocytosis or thrombocytosis) was only infrequently initiated by 
a single JAK2-mutant HSC 68. Consistent with this, some other murine models of JAK2V617F have shown that 
mutant HSCs do not have an enhanced ability to outgrow when compared to normal HSCs (reviewed in69), 
suggesting that additional factors may be required to promote clonal expansion at the level of mutant stem 
cells. However, it is worth bearing in mind that in these studies, HSC advantage is measured by the ability of 
mutant cells to outcompete normal competitors following transplantation into irradiated mice. Such a 
context may not reflect the in vivo clonal competition occurring in humans that acquire driver mutations. 
An additional complication comes from observations of heterogeneity in cell fate potential within the 
HSC/progenitor compartment in mice70,71 , raising the possibility that differences in the HSC cell-of-origin 
may affect the ability of a driver mutation to confer an advantageous cellular phenotype. Future studies 
using somatic mutations to track clonal dynamics in vivo72,73 will be better able to address whether driver 
mutations are sufficient or require additional factors for clonal outgrowth. 
 
Several lines of evidence provide clues as to the nature of additional factors that may aid positive selection 
of cells carrying a driver mutation (Figure 3). Clonal hematopoiesis increases exponentially with advancing 
age in keeping with a role for ageing in promoting clonal expansion7–9,29. The effect of age may operate at a 
cell-intrinsic level, and it is recognised that HSCs undergo a range of age-related biochemical and functional 
changes thought to result in reduced stem cell fitness74. Such alterations could favor HSCs with mutations 
that enhance aspects of stem cell fitness such as self-renewal, as shown for mutations in DNMT3A75 and 
TET276,77. Ageing may also operate at a cell-extrinsic level, with substantial changes known to occur in the 
bone marrow microenvironment, including increased inflammatory signalling and reactive oxygen species78.  
 
Other environmental factors are recognised to play a significant role in promoting clonal selection. 
Mutations in TP53 and PPM1D, thought to confer resistance to DNA damage, are prevalent in clonal 
expansions arising after chemotherapy79. In patients with therapy-related myelodysplastic syndrome (tMDS) 
or tAML, Wong et al have shown that TP53-mutated clones were present at low levels prior to any exposure 
to genotoxic agents80, and tracking of transplanted TP53 mutant cells in recipient mice demonstrated that 
the mutant HSCs only had a  clonal advantage in the context of chemotherapy. Environmental selection also 
operates in aplastic anemia and paroxysmal nocturnal hemoglobinuria which are believed to result from 
immunological or complement-mediated destruction of normal hematopoietic cells79,81. This situation is 
thought to select for genetic alterations that allow immune escape, including the expansion of clones with 
loss of heterozygosity for chromosome 6p (involving the HLA locus) and/or mutations in PIG-A 82. Complex 
crosstalk between mutant clones and an inflammatory environment is increasingly being recognised83.  Pro-
inflammmatory cytokine secretion by TET-mutant clones has been shown to modify the environment to 
enhance clonal expansion84,85. In addition, cytokine secretion by circulating mutant leucocytes has been 
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shown to result in non-hematopoeitic effects, such as increased atherosclerosis and cardiovascular 
disease86,87 .   
 
Lastly, the genetic background of an individual is also likely to influence the response to a given driver 
mutation. For example, multiple SNPs predispose to the development of an MPN88. Moreover, in a recent 
study of clonal hematopoiesis driven by chromosomal alterations, several germline loci were found to be 
associated not only with the acquisition of specific chromosomal alterations, but also with the extent of 
subsequent clonal expansion89. Lastly it is important to remember that clonal expansion may also be the end 
product of stochastically acting neutral genetic drift30,90.  
 
COOPERATING SOMATIC MUTATIONS  AND TUMOR EVOLUTION 
Despite the observation that certain hematological malignancies appear to be driven by single-gene 
mutations, the vast majority of patients with hematological cancers have additional mutations. Furthermore, 
the absolute risk of developing overt malignancy in the context of age-related clonal hematopoiesis, remains 
relatively low (0.5 - 1% per year)8,9,91, demonstrating that these drivers are usually insufficient for disease 
progression. Armitage and Doll hypothesized that cancer requires the successive and step-wise 
accumulation of multiple mutations92 in order to account for the age incidence of cancer (Figure 4), and 
subsequent investigators suggested that varying numbers of rate-limiting events are required in different 
tissues, from Knudson’s two-hit model for the development of retinoblastoma93, to at least 4-5 stages in 
colorectal cancers94. In AML multiple lines of evidence suggest that at least two driver mutations are 
required for disease development95. The dynamics of hematological disease development remain unclear 
and various models can be envisaged that might differ between them in the number of events, mutations 
or otherwise, required for disease development, and the rate of clonal expansion (Figure 4). In addition to 
the hypothesized number of lesions required to drive disease onset, sequencing of established 
hematological cancers has identified substantial intra-tumor subclonal genomic heterogeneity confirming 
ongoing acquisition of somatic mutations during tumor evolution. Clonal approaches allow assessment of 
how different mutations cooperate within cells to promote disease phenotypes, and more precise analyses 
of tumor evolutionary patterns. 
 
Cooperating somatic mutations 
Using limiting dilution xenograft transplantation of peripheral blood derived HSCs from patients with 
DNMT3A and NPM1c-mutated AML, Schlush et al, identified that the majority of transplanted mice that 
showed normal multilineage engraftment were positive only for the DNMT3A mutation96. In contrast, mice 
that regenerated hematopoiesis with a dominant myeloid blast population harbored the additional NPM1c 
mutation. This study provided two key insights. First, that AML could result from the sequential acquisition 
of two mutations, with the first mutation conferring a clonal advantage and the second mutation triggering 
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a malignant phenotype.  Secondly, that cells carrying only a DNMT3A mutation retained multilineage 
potential, providing evidence for the existence of a ‘pre-leukemic’ multipotent stem cell. Similarly, in MPNs, 
Triviai et al have shown that mutations in the chromatin modifiers ASXL1 and EZH2 have a synergistic effect 
on levels of HSC engraftment in mice97.  
 
Studies of colonies have shown that the order in which driver mutations are acquired can affect the 
behaviour of stem/progenitor cells and thus influence clonal evolution, clinical presentation and response 
to targeted therapy98,99. Using MPN samples harboring mutations in both JAK2 and TET2, Ortmann et al 
analysed colonies to determine which mutation had been acquired first.  JAK2-first and TET2-first HSCs  and 
progenitors differed in their functional properties with, for example, single JAK2-first HSCs giving rise to 
more proliferative progeny compared to TET2-first HSCs. JAK2-first patients were shown to present with 
disease at a younger age, most commonly with PV, and had an HSC/progenitor compartment comprised 
mostly of double-mutant JAK2 and TET2 cells. In contrast, TET2-first patients presented at an older age, 
more commonly with ET, and had an HSPC compartment dominated by single-mutant TET2-mutated cells. 
Outcomes and response to targeted therapy also differed significantly between the two cohorts98.  These 
data revealed the importance of mutation order for the first time in any cancer and suggested that mutation 
of TET2 alters the epigenetic landscape and thus modifies the transcriptional response to a subsequent JAK2 
mutation.  
 
Tumor evolutionary dynamics 
From bulk tumor samples, differences in the variant allele frequencies of mutations can be used to infer the 
genetic subclonal composition and phylogenetic relationships between tumor subclones100. However, such 
studies have only limited resolution, as one is restricted to analysis of only a subset of samples wherein the 
spectrum of variant allele fractions is both sufficiently large and broadly distributed. Genomic 
characterisation of either single cells or colonies, provides a ‘gold standard’ approach to construction of 
accurate tumor phylogenies and has revealed previously hidden layers of clonal complexity in a range of 
hematological malignancies101,102. For example, in acute lymphoblastic leukemia targeted genomic 
sequencing of single cells showed that structural rearrangements are acquired prior to other driver 
mutations, and that KRAS mutations are late events in tumor evolution36. Furthermore,  previously hidden 
patterns of tumor evolution have been identified. Characterisation of the breakpoints of uniparental disomy 
in JAK2V617F mutated colonies has shown that most patients with MPN harbour multiple independent 
acquisitions of JAK2V617F homozygosity66, and independently acquired mutant clones, that may also arise 
from distinct HSCs, have also been shown to co-exist in some individuals with MPN103,104,99. Similarly, single 
cell PCR analysis of the IgH locus in CLL has identified the coexistence of multiple independent clones in 
lymphoid malignancies105. Such parallel evolution suggests strong selection for specific genomic events 
during tumor evolution. 
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FUTURE DIRECTIONS 
Studies of normal and malignant hematopoiesis have pioneered the use of a range of clonal approaches.   
Through in vitro analysis of single-cell derived colonies, direct single-cell characterisation, and a variety of 
transplantation strategies, significant progress has been made in understanding the consequences of 
somatic mutations.  Lineage tracing studies using genetic markers combined with phylogenetic assessment 
has allowed us to estimate the number of human hematopoietic stem cells in the bone marrow. Such studies 
should be extended to studying clonal hematopoiesis and hematological malignancies in order to 
understand questions such as the timing of clonal expansion in individuals, the dynamics of clonal outgrowth, 
and the way in which different driver mutations exert a selective advantage within the stem cell pool. 
Technological advances in the fields of single cell ‘omics and gene-editing, will further enhance our ability to 
explore such areas.  The mechanisms which control clonal expansion and evolution, and whether these can 
be prevented, remain exciting questions for the future.  
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FIGURE TITLES AND LEGENDS 
 
Figure 1. Timeline showing a selection of hematopoietic clonal approaches. Clonal approaches illustrated 
include chromosome characterization, hematopoietic colony assays, transplantation studies and 
sequencing based techniques. Major milestones in the development of these approaches are shown in the 
timeline.15,19,20,23,38,40,41,106–110  
 
Figure 2.  Estimating the chance of acquiring a specific driver mutation within any single hematopoietic stem 
cell by 60 years of age.    Calculations use estimates provided by Lee-Six et al44 for the total HSC population 
size (between 44,000 and 215,000 cells) and the rate of mutation acquisition in individual HSCs (estimated 
to be 1 mutation every 3 weeks, or 17 mutations per year). The total number of base-pairs in the human 
genome is approximated at 3 billion. 
 
Figure 3.  Factors influencing hematopoietic clonal expansion.  A model of various stochastic and 
deterministic factors that may affect the likelihood of clonal expansion of a cell that has acquired a driver 
mutation. Combinations of risks at a given time point would additively affect the total risk.  The impact of 
each factor, and thus the shape and angle of the depicted lines, would vary depending on the specific driver 
mutation. Pie charts show potential differences in the contribution of the various factors to clonal 
expansion in the context of different driver mutations29,61,62,80.  
 
Figure 4.  Dynamics of clonal evolution during the development of hematological malignancies.  Little is 
known about the dynamics of clonal evolution following successive mutation acquisition. Six different 
models are presented (a-f). The horizontal axis is time and the vertical space represents clonal expansion. 
Green, orange and red lines represent sequential driver mutation acquisition, with red representing the 
final malignant clone. Armitage and Doll’s multi-step model of cancer development92, in which there is no 
pre-malignant clonal expansion, is shown in (a). Rare, single-driver mediated malignant transformation is 
shown in (b). In models (c-f), each mutation results in sequential clonal expansion along a path to 
malignancy. However, the dynamics of clonal expansion show different patterns. 
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